Press release
Huntington's Disease Pipeline Drugs Analysis Report, 2023: FDA Approvals, Clinical Trials, Therapies, Mechanism of Action, Route of Administration by DelveInsight | Spark therapeutics, Chong Kun Dang Pharma, Neuvivo, UniQure Biopharma, Wave Life Sciences,
"Huntington's Disease Pipeline Insight, 2023" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Huntington's Disease Market.
The Huntington's Disease Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.
Some of the key takeaways from the Huntington's Disease Pipeline Report:
https://www.delveinsight.com/sample-request/huntingtons-disease-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
• Companies across the globe are diligently working toward developing novel Huntington's Disease treatment therapies with a considerable amount of success over the years.
• Huntington's Disease companies working in the treatment market are Sangamo Therapeutics, Spark therapeutics, Chong Kun Dang Pharmaceutical, Neuvivo, UniQure Biopharma, Wave Life Sciences, Novartis, Sage Therapeutics, Annexon, Neurocrine Biosciences, Prilenia Therapeutics, and others, are developing therapies for the Huntington's Disease treatment
• Emerging Huntington's Disease therapies in the different phases of clinical trials are- TAK-686, Huntington's Disease therapy, CKD-504, NP 001, rAAV5-miHTT, WVE003, Branaplam, SAGE-718, ANX005, Valbenazine, Pridopidine, and others are expected to have a significant impact on the Huntington's Disease market in the coming years.
• In August 2022, In order to undertake a Phase I/II trial for its innovative Huntington's Disease (HD) gene treatment, BV-101, through its subsidiary BrainVectis in France, Asklepios BioPharmaceutical, a fully owned and independently run subsidiary of Bayer AG, got approval. The National Agency for Safety of Medicines and Health Products (ANSM), the nation's regulatory drug agency, has granted the corporation permission to start seeking volunteers after the relevant Ethics Committee approved the trial protocol.
• In March 2022, The PIVOT-HD Phase II clinical trial investigating PTC518 in patients with Huntington's disease (HD) has begun, according to PTC Therapeutics. An international trial called PIVOT-HD is beginning in the US. PTC518 is a small chemical splicing modifier that may be taken orally and was created specifically to reduce huntingtin mRNA and protein. The underlying cause of HD is not currently being treated.
• In January 2022, A new Phase II trial to assess tominersen in Huntington's disease (HD) has been planned, according to an announcement by Ionis Pharmaceuticals and its partner Roche. Tominersen may benefit younger adult patients with reduced disease load, according to exploratory posthoc analysis conducted after treatment in the Phase III GENERATION HD1 study was stopped. It is necessary to confirm these findings in a randomised, placebo-controlled trial.
• In September 2021, The FDA has given SAGE-718 Fast Track Designation for development as a potential treatment for Huntington's disease (HD), according to a statement from Sage Therapeutics.
• In September 2021, With the help of its unique AAV capsids, which have shown superior transgene expression in the brain compared to AAV9 delivery in non-human primates, Voyager Therapeutics unveiled new programmes for Huntington's disease, a monogenic form of ALS (SOD1), spinal muscular atrophy, and diseases associated with GBA1 mutations.
• In October 2020, To assess the effectiveness and safety of pridopidine 45 mg BID in patients with early stage HD, Prilenia started a Phase III, randomised, double-blind, placebo-controlled research. Patients who met the eligibility requirements and finished the Main Study (65 to 78 weeks) will have the option to sign up for an open-label extension.
Huntington's Disease Overview
Huntington's disease is a genetically transmitted, neurodegenerative ailment that gradually impairs cognitive function and memory (dementia) as well as the development of uncontrollable motions of the hands, feet, face, and body. Movement, mood, and cognitive abilities are all impacted by the alterations this disease brings about in the brain's central centre.
Get a Free Sample PDF Report to know more about Huntington's Disease Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/huntingtons-disease-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Emerging Huntington's Disease Drugs Under Different Phases of Clinical Development Include:
• TAK-686: Sangamo Therapeutics
• Huntington's Disease therapy: Spark therapeutics
• CKD-504: Chong Kun Dang Pharmaceutical
• NP 001: Neuvivo
• rAAV5-miHTT: UniQure Biopharma
• WVE003: Wave Life Sciences
• Branaplam: Novartis
• SAGE-718: Sage Therapeutics
• ANX005: Annexon
• Valbenazine: Neurocrine Biosciences
• Pridopidine: Prilenia Therapeutics
Huntington's Disease Route of Administration
Huntington's Disease pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical
Huntington's Disease Molecule Type
Huntington's Disease Products have been categorized under various Molecule types, such as
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy
Huntington's Disease Pipeline Therapeutics Assessment
• Huntington's Disease Assessment by Product Type
• Huntington's Disease By Stage and Product Type
• Huntington's Disease Assessment by Route of Administration
• Huntington's Disease By Stage and Route of Administration
• Huntington's Disease Assessment by Molecule Type
• Huntington's Disease by Stage and Molecule Type
DelveInsight's Huntington's Disease Report covers around 50+ products under different phases of clinical development like
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration
Further Huntington's Disease product details are provided in the report. Download the Huntington's Disease pipeline report to learn more about the emerging Huntington's Disease therapies at:
https://www.delveinsight.com/sample-request/huntingtons-disease-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Some of the key companies in the Huntington's Disease Therapeutics Market include:
Key companies developing therapies for Huntington's Disease are - Prilenia Therapeutics, Ionis Pharmaceuticals, Annexon, Vaccinex, Neurocrine Biosciences, SAGE Therapeutics, PTC Therapeutics, WaVe life Sciences, Novartis, Neurimmune Therapeutics, SOLA Biosciences, UniQure Biopharma, Roche, Annexon, Inc., Azevan Pharmaceuticals, SOM Innovation Biotech SA, Asklepios BioPharmaceutical, Luye Pharma Group Ltd., BrainStorm Cell Therapeutics, Voyager Therapeutics, Passage Bio, Locana Bio, Ceptur Therapeutics, Enzerna Biosciences, AFFiRiS AG, Arvinas, Atalanta Therapeutics, Anima Biotech, and others.
Huntington's Disease Pipeline Analysis:
The Huntington's Disease pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of Huntington's Disease with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Huntington's Disease Treatment.
• Huntington's Disease key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Huntington's Disease Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Huntington's Disease market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Download Sample PDF Report to know more about Huntington's Disease drugs and therapies-
https://www.delveinsight.com/sample-request/huntingtons-disease-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Huntington's Disease Pipeline Market Drivers
• Introduction of disease-modifying drugs, further understanding in pathogenesis are some of the important factors that are fueling the Huntington's Disease Market.
Huntington's Disease Pipeline Market Barriers
• However, lesser approved therapies, stringent regulations and other factors are creating obstacles in the Huntington's Disease Market growth.
Scope of Huntington's Disease Pipeline Drug Insight
• Coverage: Global
• Key Huntington's Disease Companies: Sangamo Therapeutics, Spark therapeutics, Chong Kun Dang Pharmaceutical, Neuvivo, UniQure Biopharma, Wave Life Sciences, Novartis, Sage Therapeutics, Annexon, Neurocrine Biosciences, Prilenia Therapeutics, and others
• Key Huntington's Disease Therapies: TAK-686, Huntington's Disease therapy, CKD-504, NP 001, rAAV5-miHTT, WVE003, Branaplam, SAGE-718, ANX005, Valbenazine, Pridopidine, and others
• Huntington's Disease Therapeutic Assessment: Huntington's Disease current marketed and Huntington's Disease emerging therapies
• Huntington's Disease Market Dynamics: Huntington's Disease market drivers and Huntington's Disease market barriers
Request for Sample PDF Report for Huntington's Disease Pipeline Assessment and clinical trials-
https://www.delveinsight.com/sample-request/huntingtons-disease-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Table of Contents
1. Huntington's Disease Report Introduction
2. Huntington's Disease Executive Summary
3. Huntington's Disease Overview
4. Huntington's Disease- Analytical Perspective In-depth Commercial Assessment
5. Huntington's Disease Pipeline Therapeutics
6. Huntington's Disease Late Stage Products (Phase II/III)
7. Huntington's Disease Mid Stage Products (Phase II)
8. Huntington's Disease Early Stage Products (Phase I)
9. Huntington's Disease Preclinical Stage Products
10. Huntington's Disease Therapeutics Assessment
11. Huntington's Disease Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Huntington's Disease Key Companies
14. Huntington's Disease Key Products
15. Huntington's Disease Unmet Needs
16 . Huntington's Disease Market Drivers and Barriers
17. Huntington's Disease Future Perspectives and Conclusion
18. Huntington's Disease Analyst Views
19. Appendix
20. About DelveInsight
Related Reports:
Huntington's Disease Market
https://www.delveinsight.com/report-store/huntingtons-disease-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Huntington's Disease Market Insights, Epidemiology, and Market Forecast-2032' report delivers an in-depth understanding of the 7MM, historical and forecasted epidemiology as well as the 7MM market trends in the United States, EU5 (Germany, France, Italy, Spain, and United Kingdom),
Huntington's Disease Epidemiology
https://www.delveinsight.com/report-store/huntingtons-disease-epidemiology-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Huntington's Disease Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, historical and forecasted Cholangiocarcinoma epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Latest Reports:
Scedosporium Infection Market https://www.delveinsight.com/report-store/scedosporium-infection-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Scedosporium Infection Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Scedosporium Infection, historical and forecasted epidemiology as well as the Scedosporium Infection market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Vascular Graft Devices Market https://www.delveinsight.com/report-store/vascular-grafts-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Vascular Graft Devices Market By Product Type (Endovascular Grafts [Abdominal And Thoracic], Access Grafts, Peripheral Grafts, And Others), By Type (Knitted, Woven, And Others), By Material (Synthetic[ Polytetrafluoroethylene [PTFE], Polyester, Polyurethane], Biological, And Others), By End User (Hospitals, Ambulatory Surgical Centers, And Others), by geography is expected to register commendable revenue growth at a steady CAGR forecast till 2027 owing to increasing prevalence of cardiovascular diseases such as aortic aneurysms and peripheral artery disease and growing patient for kidney dialysis.
Vascular Stents Market https://www.delveinsight.com/report-store/vascular-stents-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Vascular Stents Market By Product Type (Coronary Stents, Peripheral Stents [Carotid Stents, Iliac Stents, Femoral Stents, Femoral Stents, Other], Evar Stent Grafts [Abdominal Aortic Aneurysm Stents, Thoracic Aortic Aneurysm Stents]), By Type (Bare-Metal Stents, Drug-Eluting Stents), By Material (Metal And Polymer), By Mode Of Delivery (Balloon-Expandable Stents And Self Expandable Stents), By End-User (Hospitals And Ambulatory Surgical Centers), by geography, is expected to grow at a noteworthy CAGR forecast till 2027 owing to rising burden of vascular diseases across the globe and increasing preferences of minimally invasive surgeries among the patient population.
Vein Illumination Devices Market https://www.delveinsight.com/report-store/vein-illumination-devices-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Vein Illumination Devices Market Insight, Competitive Landscape and Market Forecast, 2027" report delivers an in-depth understanding of Vein Illumination Devices and the historical and forecasted Vein Illumination Devices market trends, globally, which comprises of North America, Europe, APAC, and RoW.
Recent Blog's By DelveInsight:
• Insights Into The Cutaneous T-cell Lymphoma Treatment Market
https://www.delveinsight.com/blog/cutaneous-t-cell-lymphoma-treatment-market?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Roche's HEMLIBRA: A Game Changer in Hemophilia A Treatment Landscape
https://www.delveinsight.com/blog/hemlibra-for-hemophilia-a-treatment?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Emerging Role of Digital Health in the Field of Oncology
https://www.delveinsight.com/blog/digital-health-to-improve-cancer-management?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• How Will Emerging Therapies Drift the Amyotrophic Lateral Sclerosis (ALS) Treatment Landscape
https://www.delveinsight.com/blog/evolving-als-treatment-landscape?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• How are Technological Trends and Innovations Reshaping the Dementia Care
https://www.delveinsight.com/blog/technological-innovations-in-dementia-care?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Assessing the Major Growth and Ongoing Developments in the Clinical Diagnostics Market
https://www.delveinsight.com/blog/clinical-diagnostics-market-outlook?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Non-opioid Analgesics Chronic Pain Treatment: Savior of Underserved Patients
https://www.delveinsight.com/blog/non-opioid-analgesics-for-chronic-pain-treatment?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Limited Availability and Lack of Access are Unlikely to Hinder the Billion-Dollar Alpha-1 Antitrypsin Deficiency (AATD) Treatment Market
https://www.delveinsight.com/blog/alpha-1-antitrypsin-deficiency-treatment-market?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Evaluating the Key Trends and Technologies Shaping the Future of Dentistry
https://www.delveinsight.com/blog/emerging-trends-in-dental-care-market?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
Contact Us:
Gaurav Bora
gbora@delveinsight.com
+1(919)321-6187
Healthcare Consulting
https://www.delveinsight.com/consulting-services
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Huntington's Disease Pipeline Drugs Analysis Report, 2023: FDA Approvals, Clinical Trials, Therapies, Mechanism of Action, Route of Administration by DelveInsight | Spark therapeutics, Chong Kun Dang Pharma, Neuvivo, UniQure Biopharma, Wave Life Sciences, here
News-ID: 3245335 • Views: …
More Releases from DelveInsight Business Research
Niemann-Pick Type C Pipeline Report Showcases Emerging Drugs and Leading Compani …
DelveInsight's, "Niemann Pick C Disease Pipeline Insight, 2025" report provides comprehensive insights about 10+ companies and 15+ pipeline drugs in Niemann Pick C Disease pipeline landscape. It covers the Niemann-Pick Type C pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Niemann-Pick Type C pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this…
Pemphigus Vulgaris Market Positioned for Accelerated Development Through 2034, D …
DelveInsight's "Pemphigus Vulgaris Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Pemphigus Vulgaris, historical and forecasted epidemiology as well as the Pemphigus Vulgaris market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
To Know in detail about the Pemphigus Vulgaris market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Pemphigus Vulgaris Market Forecast
https://www.delveinsight.com/sample-request/pemphigus-vulgaris-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Some of the…
Osteogenesis Imperfecta Market to Evolve Rapidly Over the Next Decade by 2034, D …
The Osteogenesis Imperfecta market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Osteogenesis Imperfecta pipeline products will significantly revolutionize the Osteogenesis Imperfecta market dynamics.
DelveInsight's "Osteogenesis Imperfecta Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Osteogenesis Imperfecta, historical and forecasted epidemiology as well as the Osteogenesis Imperfecta market trends in the United…
Myopic Macular Degeneration Market Insights Highlight Expanding Outlook Till 203 …
DelveInsight's "Myopic Macular Degeneration Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Myopic Macular Degeneration, historical and forecasted epidemiology as well as the Myopic Macular Degeneration market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
The latest healthcare forecast report provides an in-depth analysis of Myopic Macular Degeneration, offering comprehensive insights into the Myopic Macular Degeneration revenue trends,…
More Releases for Huntington
AC Company in Huntington Upgrades Emergency Response Capabilities
As temperatures climb and air conditioners are pushed to their limits, many systems begin to fail under strain.
Residents searching for a dependable ac company near me [https://summersphc.com/huntington/] in Huntington, IN, may notice faster response times and improved service delivery this summer. That's because Summers Plumbing Heating & Cooling has invested in enhancing its emergency HVAC response systems to meet the rising demand for rapid cooling solutions during heatwaves and mechanical…
Reliable AC Installation Now Available for Huntington Homeowners
Whether you're upgrading from an outdated unit or installing a brand-new system, having a team that understands your specific needs is key.
When temperatures rise and older systems falter, many homeowners start looking for AC installation near me [https://www.google.com/search?ac+installation+near+me&kgmid=/g/11tp8xn78c] to find the right solution for reliable cooling. In Huntington, a trusted name now offers convenient and professional service that makes the process easier than ever. With its long-standing reputation and customer-first…
Maycon Construction Services: Premier Roofing Solutions in Huntington
Image: https://www.globalnewslines.com/uploads/2025/01/1735918960.jpg
Huntington, NY - Maycon Construction Services is revolutionizing roofing services in Huntington with a commitment to quality, durability, and customer satisfaction. Specializing in Roof Repair Huntington [https://www.google.com/maps?cid=4993935758546148342], the company ensures homes and businesses are protected from leaks, weather damage, and structural issues.
The team at Maycon Construction Services employs state-of-the-art techniques and premium materials to deliver lasting results. Their Roof Replacement Huntington [https://www.google.com/maps/place/Maycon+Construction+Services/@38.4112395,-82.36617,17z/data=!3m1!4b1!4m6!3m5!1s0x8846079778fdc4b5:0x454e061d07439bf6!8m2!3d38.4112395!4d-82.36617!16s%2Fg%2F11sqq7wlm7?authuser=0&hl=en&entry=ttu&g_ep=EgoyMDI0MTIwOC4wIKXMDSoASAFQAw%3D%3D] services are designed to provide an upgrade…
SCHOOL OF ROCK HUNTINGTON READY TO ROCK N’ ROLL
Huntington, NY (November 17, 2016) – School of Rock, the leader in performance-based music education, announces the opening of its newest school in Huntington, New York, located at 145 East Main Street, Huntington, New York 11743. Opening on November 19, the school will host a party from 11 a.m. to 4 p.m., featuring live music from School of Rock students. In addition to the opening party, School of Rock Huntington…
Huntington Beach Real Estate Agent Launches Luxury Home Buying Experience
The Malakai Sparks Group, a Huntington Beach, California-based realty agency spearheaded by president and real estate expert Malakai Sparks, announced the launch of its Huntington Beach Home Buying Experience service, which encompasses “curated experiences” from the entire Malakai Sparks Group team. Designed for the purpose of allowing prospective buyers to take in all Huntington Beach has to offer prior to purchasing a home – while making sure the area is…
Gershow Recycling of Huntington Hosts Customer Appreciation Day
On August 24, Gershow Recycling hosted its Customer Appreciation Day at its Huntington Station facility. Those in attendance received giveaways, enjoyed food, games and the chance to win raffle prizes provided by Gershow and WBAB Radio (102.3 FM), which also provided music for the event.
Gershow has eight locations in Brooklyn, New Hyde Park, Valley Stream, Freeport, Lindenhurst, Huntington Station, Bay Shore and Medford. For more information, call (631) 289-6188…
